Study to evaluate the effects of Monoamine Oxidase–B on [18F]THK5351 brain uptake using positron emission tomography and autoradiography of human brain

Trial Profile

Study to evaluate the effects of Monoamine Oxidase–B on [18F]THK5351 brain uptake using positron emission tomography and autoradiography of human brain

Completed
Phase of Trial: Phase IV

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Fluorine 18 THK 5351 (Primary)
  • Indications Alzheimer's disease; Mild cognitive impairment; Progressive supranuclear palsy
  • Focus Diagnostic use
  • Most Recent Events

    • 29 Aug 2017 New trial record
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top